Central Bank & Trust’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Central Bank & Trust’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-696	Closed	-$41.8K	–	332
2024 Q2	$41.8K	Sell	696 -421	-38%	-$26.7K	0.01%	257
2024 Q1	$69.7K	Sell	1,117 -371	-25%	-$41.4K	0.01%	227
2023 Q4	$361K	Sell	1,488 -462	-24%	-$80.6K	0.06%	151
2023 Q3	$346K	Buy	+1,950	New	+$810K	0.06%	140

Other funds holding SXTP

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SHF

Safe Harbor Fiduciary Pensacola, Florida $105M AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Central Bank & Trust's SXTP Position: Q3 2024 in Review

Central Bank & Trust sold out of 60 Degrees Pharmaceuticals (SXTP) in Q3 2024, closing a stake of 696 shares — an estimated $41.8K sold.

Central Bank & Trust first reported a position in SXTP in Q3 2023 and held it in 4 quarters. The position peaked at $361K in Q4 2023. 6 funds tracked by Wall St. Rank hold SXTP as of Q3 2024.

Central Bank & Trust reported no remaining 60 Degrees Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Central Bank & Trust sold 696 60 Degrees Pharmaceuticals shares in Q3 2024, an estimated $41.8K.
Central Bank & Trust first reported a position in 60 Degrees Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Central Bank & Trust's 60 Degrees Pharmaceuticals position peaked at $361K in Q4 2023.
6 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q3 2024.

Based on Central Bank & Trust's 13F filing for Q3 2024, filed 30 Oct 2024.